IP Verse

Novel Pharmaceutical Composition

Patent No. EP4159205 (titled "Novel Pharmaceutical Composition") was filed by Novartis on Dec 20, 2011. The application was issued on Feb 14, 2024.

Patent Summary

Solid oral pharmaceutical dosage forms containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, which provide safe and effective treatment of cancer while maintaining therapeutic efficacy.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BENDELENov 14, 2024BENDELE
BRAND MURRAY FULLERNov 14, 2024BRAND MURRAY FULLER
GENERICS UKNov 14, 2024ELKINGTON AND FIFE
TEVA PHARMACEUTICALSNov 13, 2024D YOUNG
HAMM & WITTKOPPNov 11, 2024HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4159205

NOVARTIS
Application Number
EP22209107A
Filing Date
Dec 20, 2011
Status
Granted And Under Opposition
Jan 12, 2024
Publication Date
Feb 14, 2024
External Links
Slate, Register , Google Patents